Background {#Sec1}
==========

There has been advances in infection control practices and wound dressings yet surgical site infections (SSI) remains common in patients undergoing surgery \[[@CR1]--[@CR4]\]. European Centre for Disease Prevention and Control (ECDC) reports that SSI are among the most common healthcare-associated infections (HAIs) which occur after surgery in the area of the body where the surgery took place. European-wide SSI incidence rates range from 0.7% in knee prosthesis to 9.7% in colon surgery \[[@CR2]\]. Reddy et al. \[[@CR3]\], reported that approximately 0.3--5% of median sternotomy incisions are affected by complications, such as infection and dehiscence.

Surgical site infections impacts on morbidity, health- related quality of life, longer post-operative hospital stays, additional surgical procedures, mortality and increased costs \[[@CR4]--[@CR10]\]. Graf et al. \[[@CR6]\] estimated the financial loss to a hospital due to deep sternal wound infection following coronary artery by-pass surgery to be \$12,482 (€9154) in Germany. In the United Kingdom, attributable median hospital length of stay (LOS) due to SSI for cardiac patients is estimated to be 23 days and the attributable median costs due to SSI are £11,003 (\$8517- \$15,395) respectively \[[@CR10]\].

Many strategies have been introduced to control SSI, ranging from antibiotics prophylaxis, dressings and new protocols including the use of single use negative pressure wound therapy (sNPWT). Evidence on the clinical effectiveness of sNPWT is accumulating rapidly \[[@CR11], [@CR14], [@CR15]\] and has been shown to be effective in reducing SSI in closed incisions such as in caesarean-section, orthopaedic and cardiac surgery. Cost-effectiveness studies have been performed in patients undergoing caesarean-section \[[@CR13]\] and Orthopaedic surgery \[[@CR12]\], however the cost-effectiveness of sNPWT following cardiothoracic surgery has not been reported.

This study therefore examined the cost-effectiveness of sNPWT PICO^◊^ (Smith & Nephew, Hull, UK) compared with standard care dressing (standard post-operative dressings) in preventing surgical site complications defined as dehiscence and sternotomy infections in patients undergoing coronary artery by-pass (CABG) surgery from a Germany Insurance payer's perspective.

Methods {#Sec2}
=======

To describe the clinical problem, we constructed a decision analytic model in Microsoft Excel 2016 (Microsoft Corporation, Redmond, WA, US) to simulate the expected outcomes and costs of patients undergoing CABG surgery. The mean age of patients that were modelled is 65 years, which represents the mean age of the majority of patients included in the studies were baseline and effectiveness data were drawn from \[[@CR16], [@CR17]\]. Following skin closure, one group would be managed by sNPWT while the other group would receive standard of care dressings. The modeled patients may develop complications of sternotomy wounds which in this model was defined as SSI (superficial and deep wound infections) or dehiscence. The complications are assumed to result in readmissions and revision surgery in some cases as shown in Fig. [1](#Fig1){ref-type="fig"}. The model assumed a proportion of patients could die from natural causes and also die due to surgery. The perspective adopted was that of the Statutory Health Insurance payers in Germany. The economic model adopted a 12 week time horizon to enable the both superficial and deep infection to manifest themselves. Superficial SSI usually occurs within 30 days after surgery while deep SSI normally occurs within 30 to 90 days following surgery \[[@CR1]\]. No discounting was done for both costs and outcomes due to a shorter time horizon (12 weeks). The schematic representation of the model is shown below in Fig. [1](#Fig1){ref-type="fig"}, showing the branches of the complications node, there are similar branches for the no complications node not shown in the figure.Fig. 1Model structure for sNPWT compared to SC in patients following CABG surgery. The decision tree model used to predict cost and outcome of sNPWT and standard of care. The tree maps the outcomes (health states) modelled following a complication or no complication. The branches for no complication are not shown in the figure

Baseline clinical data {#Sec3}
----------------------

Data for this economic analysis were derived from published clinical studies. In particular the baseline data was obtained from a single centre prospective observational study that followed patients who underwent CABG for 36 months in Germany \[[@CR16]\]. The study collected information on the following outcomes; revision operations, patients' length of stay, and readmissions to the hospital from 2621 patients. Twenty-seven patients (4.85%) were diagnosed SSI according to the Centres for Disease Control and Prevention criteria. Data on length of stay, readmission, revision surgery and mortality due to surgery was taken from the same source \[[@CR16]\].

Effectiveness data for sNPWT was taken from a randomised open label trial conducted in Poland \[[@CR17]\]. The study evaluated sNPWT use in patients after an off-pump CABG procedure, using the internal mammary artery in 80 patients. There were 40 patients in each arm with similar patient characteristics ie, 40 in sNPWT and 40 in the standard care arm in whom conventional dressings were applied in the postoperative period. The ECDC definition of SSI was used in this study. The endpoint of the study was wound healing defined as absence of SSI and wound dehiscence of wound margins without clinical or microbiological signs of infections. 37/40 (92.5%) patients had their wounds healed without complications in the sNPWT compared to 30/40 (75%) patients in the standard care group *p* = 0.03 \[[@CR17]\]. We calculated the Odds ratio (OR) from this data to be, OR;0.22, 95% confidence interval 0.06 to 0.81, *p* = 0.002 We are also aware of an ongoing study in Spain which is comparing sNPWT with standard of care in patients undergoing CABG with preliminary results expected in 2019 (Dr Carlos Velasco, Hospital Juan Canalejo, Spain; − personal communication).

Strugala and Martin found that sNPWT reduced length of stay on average by 0.5 days \[[@CR14]\] in a meta-analysis that assessed the prophylactic use of PICO negative pressure wound therapy on surgical site complications. We applied this reduction in the base case model and assessed the assumption that there was no difference in sensitivity analysis. All-cause mortality was obtained from the Germany Federal Statistical Office \[[@CR18]\]. We made a further assumption that mortality following revision surgery will be 30% higher than that of patients who did not have revision surgery in accordance to published literature \[[@CR19]\]. The clinical data used in the model is shown in Table [1](#Tab1){ref-type="table"}.Table 1Clinical and utility data used in the model for sNPWT compared to standard care in patients following CABG surgery. The table shows the baseline data, effectiveness of sNPWT and health related quality of life (utility) data that was applied in the modelOutcomeMeanNumber of patientsEventsDistributionReferenceBaseline SSC rate0.0482621127BetaCristofolini \[[@CR16]\]Mortality with SSC0.0171182BetaibidMortality without SSC0.007250318BetaReadmission SSC0.0341184BetaReadmission No SSC0.00025031BetaRevision SSC0.0681188BetaRevision No SSC0.005250312BetaAll-cause mortality0.003\[[@CR18]\]Multiplier for revision mortality1.300Wu \[[@CR19]\]Length of stay data Length of stay with surgical site complicationsMeanLower CIUpper CI Intensive care unit15.2187.2Log normalCristofolini \[[@CR16]\] Intermediate care4.80.525.2Log normal General ward22.30.568.4Log normalLength of stay without surgical site complications Intensive care unit3.8126Log normalCristofolini \[[@CR16]\] Intermediate care2.40.510Log normal General ward8.30.519Log normalUtility data used in the model ParameterMeanAlphaBetaDistributionSource Disutility with SSI0.2841BetaTuffaha \[[@CR13]\] Utility with no SSI0.9118518BetaEffectiveness data (Odds ratio and 95% CI) OutcomeMeanLower CIUpper CIDistributionSource Odds ratio for SSC0.2200.0600.810Log normalWitt-Majchrzak \[[@CR17]\] Reduction in LOS (days)0.5000.0200.70Log normalStrugala \[[@CR14]\]Abbreviations: *sNPWT* single use negative pressure wound therapy, *SSC* surgical site complications, *CI* confidence interval, *LOS* length of stay

Health state utilities {#Sec4}
----------------------

The health state utilities in the model were sourced from published literature. The utility scores for patients undergoing CABG and discharged without complications were set at 0.91 and for those discharged with complications was set at 0.71 obtained from a study by Tuffaha 2015. The study by Tuffaha et al. considered the cost-utility analysis of negative pressure wound therapy in high-risk caesarean section wounds \[[@CR13]\]. Currently there is no evidence that utility values differ by type of dressing used, we therefore assumed that utility was independent of the type of dressing in the model. The utility data parameters used in the model is shown in Table [1](#Tab1){ref-type="table"}.

Cost data {#Sec5}
---------

Costs were derived from standard cost references with resource utilisation valued in Euros (2017). For inpatient care we used data from Cristofolini who identified length of stay in different hospital wards from intensive care unit to the general ward before discharge for patients with or without infections. We calculated the mean cost for a patient with or without infection and applied it in the model. The cost for the stay in each ward were obtained from the hospital management website \[[@CR20]\]. For procedure costs, we used the average reimbursement costs from the relevant Germany Diagnosis Related Group Report Browser 2017 of the procedure code 5--361 "Application of an aortocoronary bypass", and Procedure code 5--363.1: "Revision of an aortocoronary bypass" see Table [2](#Tab2){ref-type="table"}. The mean cost for the main procedure was estimated to be €15,135.58, while for revision it was estimated to be €24,740.45. We assumed that costs of standard of care dressings and nursing costs were all included in the DRG costs while the cost of the intervention (sNPWT) was obtained from the manufacturer. The model applied the cost of one sNPWT device, which is designed to last for 7 days and is supplied with two dressings. In the sensitivity analysis we assumed patients received two sNPWT dressings to assess changes in expected total costs.Table 2Cost data used in the model for sNPWT compared to standard care in patients following CABG surgeryCost componentMean costLower valueUpper valueSourceCost of hospital stay in ICU ward (inclusive of all done inpatient)€1400.00€1050.00€1750.00\[[@CR20]\]Intermediate ward€850.00€637.50€1062.50ibidGeneral ward cost/day€200.00€150.00€250.00CABG procedure (code 5--361.^a^: "Application of an aortocoronary bypass")€15,135.58€11,351.69€18,919.48ibidCost of revision CABG procedure€24,740.45€18,555.34€30,925.56ibidOutpatient rehabilitation€1726.46€1294.85€2158.08\[[@CR21]\]Community doctor consultation fee per quarter€16.53€12.40€20.66\[[@CR22]\]Electrocardiography€16.53€12.40€20.66ibidCommunity Cardiologist€21.06€15.80€26.33ibidDuplex-Electrocardiography€71.50€53.63€89.38ibidHome visits€11.53€8.65€14.41ibidsNPWT unit cost€153.00€114.75€191.25^a^Abbreviations: *CABG* coronary artery bypass grafting, *sNPWT* single use negative pressure wound therapy, Gamma distribution was used for costs, we assumed the cost values will be 25% above and below the mean value to calculate the lower and upper values. ^a^Data obtained from manufacturer

For post discharge outpatient consultations, we assumed patients would be seen in an outpatient rehabilitation facilities for 3 weeks. Rehabilitation costs were obtained from a study by Zeidler et al. \[[@CR21]\] which considered cost of outpatient and inpatient rehabilitation for cardiac diseases in Germany. Mean costs were inflated to 2018 using the Germany consumer price index and were estimated to be €1726.47 for outpatient rehabilitation which included the costs of 25--30 min of physiotherapy once per week for 3 weeks. In addition, we included the costs of one community doctor and community cardiologist visit where an electrocardiography a duplex-electrocardiography would be done respectively. Furthermore, the cost of once a week visit by a community nurse for 6 weeks was also estimated \[[@CR22]\]. Cost of post-surgery medication was assumed to be the same ie, patients were all prescribed antiplatelet, statins, beta-blockers, ACE inhibitors and was therefore not explicitly costed. The relevant costs and their sources are presented in Table [2](#Tab2){ref-type="table"}.

Cost-effectiveness and sensitivity analysis {#Sec6}
-------------------------------------------

The incremental cost-effectiveness ratio is the added cost per additional unit of health, in this model measured in quality adjusted life years (QALYs) and complications avoided. This was calculated as the difference between the expected costs divided by the expected difference between the QALYs or complications avoided of sNPWT and standard care over the modelled time horizon.

Sensitivity analysis was done to assess the uncertainty around the model inputs and their impact on the main conclusions of the model. One-way sensitivity analyses were conducted by varying some of the critical model parameters, each key parameter was alternately assigned a low and high value then re-evaluate the cost-effectiveness results. Furthermore, we implemented a probabilistic sensitivity analysis where we assigned prior distributions to model parameter and then simultaneously selecting values at random from those distributions using Monte Carlo simulation to estimate the expected costs and effects associated with each intervention. The lognormal distribution was implemented to capture the uncertainty surrounding the treatment effect; the gamma and beta distributions were used to capture the uncertainty in cost and utility values respectively.

Results {#Sec7}
=======

The total mean costs per patient in the sNPWT group were lower than the total mean costs per patient in the standard care group. The use of sNPWT was associated with more QALYs and fewer wound related complications compared to the use of standard care. Overall, the use of sNPWT is a dominant strategy (cost-saving) compared to standard care as it costs less and results in better clinical outcomes as shown in Table [3](#Tab3){ref-type="table"}.Table 3Base case results for sNPWT compared to standard care in patients following CABG surgeryInterventionCostsComplications avoidedQALYsCost differenceComplication differenceQALY differenceStandard of care€ 20,5720.9520.8593sNPWT€ 19,9860.9890.8904-€ 5860.03740.0311Abbreviations: *sNPWT* single use negative pressure wound therapy, *QALY* quality adjusted life years

Sensitivity analysis {#Sec8}
--------------------

One-way sensitivity analyses was performed and the results are displayed in Table [4](#Tab4){ref-type="table"} showing the mean incremental costs of sNPWT compared to standard care. Negative costs shows that sNPWT is cost-saving compared to standard care, hence model's conclusions were not changed by changes in input parameters tested as shown in Table [4](#Tab4){ref-type="table"} where all the cost differences are below €0.Table 4Results of one way-sensitivity analysis for sNPWT compared to standard care in patients following CABG surgeryParameter, mean value (lower and upper value)Savings with lower valueSavings with upper valueBaseline Risk 4.8% (2.5% and 7.8%)€ 428€ 793Treatment effect complications 0.22 (0.06 and 0.81)€ 654€ 337Cost of sNPWT €153 (€114.75 and €191.25)€ 624€ 548Number of sNPWT 1 (2)€ 433Length of stay difference 0.5 (0)€ 178Abbreviations: *sNPWT* single use negative pressure wound therapy

We also performed a probabilistic sensitivity analysis, and presented the results as cost-effectiveness acceptability curves and the cost-effectiveness plane. The cost-effectiveness acceptability curves illustrate the probability that an intervention is cost-effective compared with the alternative, for a range of maximum monetary values that a decision-maker is willing to pay for a unit change in outcome in this case measured in QALYs. In our model, the cost-effectiveness acceptability curves demonstrates that sNPWT is 100% cost-effective for the willingness-to-pay threshold figure of €50,000 as shown in Fig. [2](#Fig2){ref-type="fig"}. The cost-effectiveness plane shows that both incremental cost and incremental QALY estimates are associated with little uncertainty as 99% of samples (red dots) are located in the South East (SE) quadrant where sNPWT is associated with less costs and better clinical outcomes as shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 2Cost effectiveness acceptability curves for sNPWT compared to standard care in patients following CABG surgery. Cost-effectiveness acceptability curves depicting results of the probabilistic sensitivity analysis for the two interventions sNPWT and SC. The y-axis gives the probability that each intervention is cost effective as a function of willingness to pay shown on the x-axis. A willingness to pay of €50,000/QALY is within the bounds of accepted cost-effectiveness thresholds. The figure suggests there is little uncertainty regarding the cost-effectiveness of sNPWT compared to SC (100% probability that sNPWT is cost-effective)Fig. 3Cost-effectiveness plane for sNPWT compared to standard care in patients following CABG surgery. The cost-effectiveness plane shows results of the probabilistic sensitivity analysis for the two interventions sNPWT and SC. Each point on the plot corresponds to one trial in the Monte-Carlo simulation (2000 simulations were conducted) comparing the incremental effectiveness and incremental costs of sNPWT compared to SC. Costs for sNPWT were consistently lower (read on the y-axis) and effectiveness highest (read on the x-axis) for the SSC prevention following CABG compared to SC. The figure therefore shows that sNPWT is cost-saving

Subgroup analysis {#Sec9}
-----------------

A study by Olsen 2002 et al. \[[@CR23]\] which considered the risk factors for deep and superficial SSI after CABG surgery indicates that the risk of deep chest SSI was associated with a combination of obesity and diabetes, whereas increased risk of superficial chest SSI was associated primarily with obesity. In our analysis we considered the sub-group of patients with obesity, diabetes and smoking. The risk of SSI was increased by more than threefold for patients with BMI \> 30 while for diabetes and smoking it's more than 2.5 fold. In these high risk patients, sNPWT was shown result in greater savings when compared to standard care in patients following CABG surgery. Table [5](#Tab5){ref-type="table"} shows the results of the sub-group analysis. Bigger savings are observed when patients with BMI ≥ 30 are prophylactically treated with sNPWT than with standard care dressings.Table 5Sub-group analysis results for sNPWT compared to standard care in patients following CABG surgerySub-groupCost saving with sNPWTAdditional QALYs due to sNPWTReduction in complications due to sNPWTBMI ≥ 30€ 15860.11470.1507Diabetes€ 13700.0960.1262Smoking€ 12980.08980.118Abbreviations: *sNPWT* single use negative pressure wound therapy, *BMI* body mass index, *QALYs* quality adjusted life years

Discussion {#Sec10}
==========

This study examined the cost-effectiveness analysis of sNPWT compared to standard of care dressings in preventing SSI for patients undergoing CABG. The results of the study suggest that treating patients undergoing CABG with sNPWT is cost-saving resulting better clinical outcomes (0.311 more QALYs) and cheaper overall, with cost savings of €586 per patient. The probability of sNPWT being cost-effective is 100%, indicating decision certainty and little chance of error in a decision based on this cost-effectiveness analysis.

A limited number of cost-effectiveness studies evaluating the use of sNPWT in closed incisions have been published \[[@CR12], [@CR13]\] and they conclude that negative pressure wound therapy is cost-effective. However, to our knowledge, there is no published data on cost-effectiveness analysis of sNPWT in preventing wound complications following CABG surgery. This may be explained by lack of clinical evidence to support sNPWT as we found out during the literature search. As noted earlier, we are aware of an ongoing clinical trial comparing sNPWT with standard care following CABG surgery (Dr Carlos Velasco; Hospital Juan Canalejo, Spain; personal communication).

The model adopted a number of conservative assumptions so the projected savings may actually under-estimate the true financial impact. For instance, we only captured SSI as an outcome and did not include other outcomes such as healing. Potentially infected wounds will take longer to heal and might develop into chronic wounds which are costly to treat \[[@CR24]\]. Equally, dressing changes was not captured as an outcome, however we know based on previous studies that infected wounds would require more dressing changes making the model conservative favoring the strategy with more SSIs. For instance there were few dressing changes in the sNPWT group (*p* = 0.002) compared to standard care after hip and knee surgery, while there were more wounds with superficial infections in the standard care arm \[[@CR11]\].

Given the diversity of health systems across the world, the results of this analysis should be interpreted with caution. We acknowledge that the reimbursement systems, relative prices, and treatment practices, are important issues that vary from country to country hence country-specific assumptions may be required. However, we note that our cost-effectiveness results were tested in sensitivity analysis and the RCT measured SSI in a standard way using the ECDC matrix. A study by Hansen 2012, found that there was a high degree of concordance between European and US case definitions of healthcare-associated infections \[[@CR25]\]. Therefore, the measurement of SSI in a standard way suggests that the results of the RCT which drive the cost-effectiveness are likely to be replicated in setting with similar baseline risks. Furthermore, our model is based on clinical data that comes from a single center RCT, multi center trials should be preferred as they yield data which is easily generalisable. We therefore encourage other scholars to update the economic model once additional evidence becomes available.

Conclusions {#Sec11}
===========

Our analysis found sNPWT to be less costly and more effective (dominant), resulting in an overall cost decrease of €586 per patient when used prophylactically in patients undergoing coronary artery by-pass surgery. These results remained stable in sensitivity analyses with bigger savings identified in sub-groups of patients with elevated risk of surgical site complications such as those patients with diabetes, obese and smokers. We however recommend that additional economic studies should be conducted as new evidence on the use of sNPWT in CABG patients becomes available to validate the results of this economic analysis.
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